ClinConnect ClinConnect Logo
Search / Trial NCT02814435

Quality of Life Measures in Patients With Retinal Degeneration

Launched by UNIVERSITY OF OXFORD · Jun 24, 2016

Trial Information

Current as of July 21, 2025

Completed

Keywords

Retina Retinal Degeneration Quality Of Life Measures

ClinConnect Summary

IRD presents a significant burden on the NHS as well as on the individual and families. IRDs are particularly difficult in a family situation due to guilt and other complex emotions related to inheritance patterns. Poorer mental health has been reported in patients with retinitis pigmentosa, manifesting in a range of ways including stress, depression and anxiety, particularly as the disease progresses. This is most probably caused by the uncertainty of the disease process and the progressive nature of the degeneration.

Recent work has reported that quality of life significantly deteriorate...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Participant is willing \& able to give informed consent for participation in the study.
  • Male or female, aged 18 - 85.
  • A clinical or genetic diagnosis of retinal degeneration or normal age and sex-matched controls without known retinal disease.
  • Able to participate in visual function testing.
  • Exclusion Criteria:
  • * The participant may not enter the study if any of the following apply:
  • 1) they have a pre-existing amblyopia or squint;
  • 2) they have any other retinal problems that may confound the measures assessed.

About University Of Oxford

The University of Oxford, a prestigious institution renowned for its excellence in research and education, serves as a leading clinical trial sponsor dedicated to advancing medical science and improving patient care. With a rich history of innovation and a multidisciplinary approach, the university leverages its extensive expertise in various fields, including medicine, public health, and biomedical research, to conduct rigorous clinical trials. Collaborating with healthcare professionals, industry partners, and regulatory bodies, the University of Oxford aims to translate groundbreaking research findings into effective therapies and interventions, contributing to the global effort of enhancing health outcomes.

Locations

Oxford, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Jasleen K Jolly, MSc

Principal Investigator

University of Oxford

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials